Emmaus Life Sciences licenses IRAK4 inhibitor KM10544 from Kainos for cancer treatment

Emmaus Life Sciences, Inc.

Exclusive license for U.S., U.K., EU to Kainos' IRAK4 inhibitor KM10544 for cancers including leukemia, lymphoma, solid tumors.
Six-figure upfront cash payment; mid-eight-figure milestones; single-digit royalty on net sales; similar sublicensing fee.
Emmaus plans in-vivo studies, IND-enabling studies, and seeks Orphan Drug Designation.
Agreement expands existing R&D collaboration between Emmaus and Kainos.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.